CLIA Adiponectin

Chemiluminescence kit for the detection of adiponectin in human serum.

Coming soon
Catalog Number: CL-ADP050
Size: 50 tests
Regulatory status: CE IVD
Clinical topic: Diabetes & Metabolism Disorders
Diagnostic panel: Female & Male Fertility
Metabolic Syndrome Panel
CLIA Adiponectin
  • Assessing risk of metabolic syndrome, prediabetes, T2DM, and GDM
  • Correlates with abdominal visceral fat (AVF) independently from BMI
  • Adiponectin/leptin ratio is a marker of cardiometabolic risk
  • Assessing Increased risk of some cancers

Adiponectin (also referred to as Acrp30) is a protein hormone produced by adipose tissue (adipokine). Adiponectin inhibits glucose synthesis in the liver, increases the tissue response to insulin, and enhances fatty acid oxidation in skeletal muscle. Its levels are positively correlated with many "beneficial" and negatively with "harmful" metabolic markers. Adiponectin acts as a strong protective factor against disorders associated with obesity and especially visceral fat adiposity. It exhibits protective function in the initiation and progression of atherosclerosis. The anti-inflammatory effect of adiponectin may be a major component of its positive effect in the suppression of cardiovascular and metabolic diseases, including atherosclerosis and insulin resistance. Adiponectin also suppresses tumor progression by a mechanism involving its Adipo R1 and Adipo R2 receptors.
The implementation of adiponectin as an innovative parameter on the automated platform KleeYa® makes it available to the public.

Metabolic syndrome and T2DM
Low adiponectin levels indicate an increased risk of metabolic syndrome, insulin resistance, prediabetes, type 2 diabetes mellitus (T2DM), gestational diabetes (GDM), NAFDL, and cardiovascular events, especially atherosclerosis. Adiponectin/leptin ratio is even more sensitive than adiponectin or leptin alone.

Cardiovascular diseases
Adiponectin exhibits antiatherogenic and anti-inflammatory effects and patients with low adiponectin are at an increased risk of CVD like atherosclerosis and coronary artery disease.

Cancer
Low levels of adiponectin indicate an increased risk of some malignancies like breast cancer and prostate carcinomas.

Technical specifications

Technical data
References
Related Products

Technical data

Assay time15 min
Assay stability (on board)30 days
Sample matrix Serum
Sample volume10 µL
Sample stability7 days at 2-8 °C, 24 months at -20 °C
Concentration range25 – 800 ng/ml
Assay/kit contentReagent Cartridge with specific reagents for the assay, magnetic particles, calibrators
Complementary productsWash buffer, Anchor® Tips, Stackable cuvettes, Trigger solutions

References

References to CLIA Adiponectin

  • Wang ZV, Scherer PE. Adiponectin, the past two decades. J Mol Cell Biol. 2016 Apr;8(2):93-100. doi: 10.1093/jmcb/mjw011. Epub 2016 Mar 18. PMID: 26993047; PMCID: PMC4816148.
    See more on PubMed
  • Nigro E, Scudiero O, Monaco ML, Palmieri A, Mazzarella G, Costagliola C, Bianco A, Daniele A. New insight into adiponectin role in obesity and obesity- related diseases. Biomed Res Int. 2014;2014:658913. doi: 10.1155/2014/658913. Epub 2014 Jul 7. PMID: 25110685; PMCID: PMC4109424.
    See more on PubMed
  • Otto C, Otto B, Göke B, Pfeiffer AF, Lehrke M, Vogeser M, Spranger J, Parhofer KG. Increase in adiponectin levels during pioglitazone therapy in relation to glucose control, insulin resistance as well as ghrelin and resistin levels. J Endocrinol Invest. 2006 Mar;29(3):231-6. doi: 10.1007/BF03345545. PMID: 16682836.
    See more on PubMed
  • Moon HU, Ha KH, Han SJ, Kim HJ, Kim DJ. The Association of Adiponectin and Visceral Fat with Insulin Resistance and β-Cell Dysfunction. J Korean Med Sci. 2018 Dec 26;34(1):e7. doi: 10.3346/jkms.2019.34.e7. PMID: 30618514; PMCID: PMC6318440.
    See more on PubMed
  • Li S, Shin HJ, Ding EL, van Dam RM. Adiponectin levels and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA. 2009 Jul 8;302(2):179-88. doi: 10.1001/jama.2009.976. PMID: 19584347.
    See more on PubMed
  • Lindberg S, Jensen JS, Bjerre M, Pedersen SH, Frystyk J, Flyvbjerg A, Galatius S, Jeppesen J, Mogelvang R. Adiponectin, type 2 diabetes and cardiovascular risk. Eur J Prev Cardiol. 2015 Mar;22(3):276-83. doi: 10.1177/2047487313514894. Epub 2013 Nov 21. PMID: 24265290.
    See more on PubMed
  • Kashiwagi R, Yamada Y, Ito Y, Mitsui Y, Sakaue T, Iwamoto R, Saisho K, Tamba S, Yamamoto K, Watanabe T, Fujimoto T, Iwahashi H, Matsuzawa Y. Increase in Adiponectin Level Prevents the Development of Type 2 Diabetes in Japanese Men With Low Adiponectin Levels. J Endocr Soc. 2018 Jun 14;2(7):753-764. doi: 10.1210/js.2018-00033. PMID: 29978152; PMCID: PMC6030829.
    See more on PubMed
  • Baden MY, Yamada Y, Obata Y, Hosakawa Y, Saisho K, Tamba S, Yamamoto K, Umeda M, Furubayashi A, Tsukamoto Y, Matsuzawa Y. Serum adiponectin level is not only decreased in metabolic syndrome but also in borderline metabolic abnormalities. Nutr Diabetes. 2011 Oct 10;1(10):e18. doi: 10.1038/nutd.2011.13. PMID: 23455020; PMCID: PMC3302140.
    See more on PubMed
  • Hui X, Lam KS, Vanhoutte PM, Xu A. Adiponectin and cardiovascular health: an update. Br J Pharmacol. 2012 Feb;165(3):574-90. doi: 10.1111/j.1476-5381.2011.01395.x. PMID: 21457225; PMCID: PMC3315032.
    See more on PubMed
  • Dalamaga M, Diakopoulos KN, Mantzoros CS. The role of adiponectin in cancer: a review of current evidence. Endocr Rev. 2012 Aug;33(4):547-94. doi: 10.1210/er.2011-1015. Epub 2012 Apr 30. PMID: 22547160; PMCID: PMC3410224.
    See more on PubMed
  • Frühbeck G, Catalán V, Rodríguez A, Gómez-Ambrosi J. Adiponectin-leptin ratio: A promising index to estimate adipose tissue dysfunction. Relation with obesity-associated cardiometabolic risk. Adipocyte. 2018 Jan 2;7(1):57-62. doi: 10.1080/21623945.2017.1402151. Epub 2017 Dec 5. PMID: 29205099; PMCID: PMC5915018.
    See more on PubMed
  • Behrouz V, Jazayeri S, Aryaeian N, Zahedi MJ, Hosseini F. Effects of Probiotic and Prebiotic Supplementation on Leptin, Adiponectin, and Glycemic Parameters in Non-alcoholic Fatty Liver Disease: A Randomized Clinical Trial. Middle East J Dig Dis. 2017 Jul;9(3):150-157. doi: 10.15171/mejdd.2017.66. PMID: 28894517; PMCID: PMC5585907.
    See more on PubMed
  • Bobbert T, Rochlitz H, Wegewitz U, Akpulat S, Mai K, Weickert MO, Möhlig M, Pfeiffer AF, Spranger J. Changes of adiponectin oligomer composition by moderate weight reduction. Diabetes. 2005 Sep;54(9):2712-9. doi: 10.2337/diabetes.54.9.2712. PMID: 16123361.
    See more on PubMed
  • van Gemert WA, Monninkhof EM, May AM, Elias SG, van der Palen J, Veldhuis W, Stapper M, Stellato RK, Schuit JA, Peeters PH. Association between changes in fat distribution and biomarkers for breast cancer. Endocr Relat Cancer. 2017 Jun;24(6):297-305. doi: 10.1530/ERC-16-0490. Epub 2017 May 16. PMID: 28512158.
    See more on PubMed

Related Products

Do you want to learn more?
We're here for you

Please fill in
all fields
marked *
Up
This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.
Find out more here.
Agree